ALK and neoplasm: As expected, in another GEM model expressing the EML4‐ALK fusion oncogene with the L1196M mutation (n = 3) (Chen et al, 2014), substantial tumor regression was also observed within one week of treatment with 40 mg/kg XMU‐MP‐5 twice daily (Fig 5C and Appendix Fig S10B).